阿可拉定联合常规方案治疗晚期非小细胞肺癌的疗效和安全性评价  

Effectiveness and safety of icaritin combined conventional regimen in treatment of advanced non-small cell lung cancer

作　　者：周鑫 赵卫红 赵晓[1] 秦博宇 焦顺昌[1] ZHOU Xin;ZHAO Weihong;ZHAO Xiao;QIN Boyu;JIAO Shunchang(Department of Medical Oncology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心肿瘤内科,北京100853

出　　处：《解放军医学院学报》2019年第3期219-222,共4页Academic Journal of Chinese PLA Medical School

基　　金：吴阶平医学基金会临床科研专项资助基金(320.6750.17191)~~

摘　　要：目的探讨阿可拉定联合常规方案对二线或多线治疗耐药后晚期非小细胞肺癌的疗效及安全性。方法纳入2017年1月-2018年10月在解放军总医院第一医学中心肿瘤内科治疗的晚期非小细胞肺癌患者33例,根据常规治疗方案中是否联合阿可拉定分为阿可拉定组及常规治疗组。其中阿可拉定组14例,常规治疗组19例,观察两组的近期疗效、无进展生存时间(progress-free survival,PFS)及不良反应。结果两组年龄、性别、病理类型、肿瘤大小、分期、治疗方案、治疗线数等基线资料差异无统计学意义(P> 0.05),mPFS阿可拉定组为5个月,常规治疗组为3个月,两组差异有统计学意义(P=0.002)。阿可拉定组客观缓解率(overall response rate,ORR)和疾病控制率(disease control rate,DCR)均高于常规治疗组(ORR:7.14%vs 5.26%;DCR:78.6%vs53.2%),但差异无统计学意义。两组Ⅲ～Ⅳ级不良反应的类型及发生率无统计学差异。结论采用阿可拉定联合常规方案治疗晚期非小细胞肺癌具有一定的临床疗效,且安全耐受性好。Objective To investigate the effectiveness and safety of icaritin combined conventional regimen in the treatment of advanced non-small cell lung cancer after failure of second-line or multiline therapy.Methods Thirty-three patients with advanced non-small cell lung cancer treated in our department from January 2017 to May 2018 were divided into icaritin group and conventional therapy group according to whether they were treated with icaritin on the basis of conventional treatment plan.There were 14 patients in the icaritin group and 19 patients in the conventional therapy group,and their short-term effectiveness,PFS and adverse reactions were observed.Results There was no signicant difference in age,sex,pathological type,tumor size,stage,treatment plan and treatment line between the two groups(P>0.05).The mPFS of the icaritin group was 5 months,signicantly longer than 3 months in conventional treatment group(P=0.002).The ORR and DCR of the icaritin group were higher than those of the conventional treatment group(ORR:7.14%vs 5.26%;DCR:78.6%vs 53.2%),without statistically signicant difference.There was no signicant difference in the types and incidence of gradesⅢ-Ⅳadverse events between two groups.Conclusion Treating advanced non-small cell lung cancer with a combination of icaritin and conventional regimens has certain clinical effect and is well tolerated.

关 键 词：阿可拉定 晚期非小细胞肺癌 疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]